Correlations between the patient microbiome with response and development of immune mediated adverse effects to immunotherapy in lung cancer

Immune checkpoint inhibitors comprise a rapidly burgeoning treatment modality in multiple cancers, but outcomes to treatment, including tumor regression/response and immune-mediated adverse events, are highly variable for as yet unclear reasons. Our project seeks to identify any associations tying fecal, oral and respiratory microbiomes to immunotherapy treatment response and toxicities in lung cancer, as well as each other.

免疫检查点抑制剂（Immune Checkpoint Inhibitors）是当前多种癌症治疗领域快速发展的治疗手段，但包括肿瘤消退/应答以及免疫介导不良事件在内的治疗结局存在显著异质性，目前其具体成因尚不明确。本研究旨在明确粪便、口腔及呼吸道微生物组（microbiomes）与肺癌患者免疫治疗应答、治疗毒性之间的关联，同时探究这三类微生物组之间的相互关系。